Scholar Rock Holding Corporation announced that the underwriters of its recent public offering fully exercised their option to purchase additional shares. This exercise involved 1,592,920 additional shares of common stock at the public offering price of $28.25 per share.
The full exercise resulted in approximately $45 million in additional gross proceeds for Scholar Rock, before deducting underwriting discounts and commissions and offering expenses. The closing of this transaction occurred on October 18, 2024.
This additional capital further strengthens the company's financial position, providing more resources to support the commercialization of apitegromab and advance its clinical and preclinical pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.